[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603230":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":18,"locations":28,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Beijing Suncadia Pharmaceuticals Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-1918","EXPERIMENTAL",null,[13],"Drug: SHR-1918",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":11},"DRUG",[9],[19,24],{"name":20,"role":21,"phone":22,"phoneExt":11,"email":23},"Meng Sun","CONTACT","+86 18036618718","meng.sun@hengrui.com",{"name":25,"role":21,"phone":26,"phoneExt":11,"email":27},"Chao Lyu","+86 13810733217","chao.lv.cl1@hengrui.com",[29],{"facility":30,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Xiangya Second Hospital of Central South University","Changsha","Hunan","410007","China","CN",{"type":37,"coordinates":38},"Point",[39,40],112.97087,28.19874,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":11,"phoneExt":11,"email":11},"Daoquan Peng","PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603230","phase-2-evaluate-the-long-term-efficacy-and-safety-of-shr-1918-in-patients-with-homozygous-familial-hypercholesterolemia-100603230",false,"NCT07133815","Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia","A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Subjects who received and completed the SHR-1918-301 study treatment in previous studies and were deemed to have therapeutic benefits by the researchers\n\nExclusion Criteria:\n\n1. Known to be allergic to the investigational drug or any component of the investigational drug, or to have experienced severe allergic reactions to other antibody drugs;\n2. History of malignant tumors in the past 5 years;\n3. There are serious concurrent diseases\n4. Pregnant or lactating women;\n5. The researchers determined that the subjects had poor compliance or any inappropriate factors for participating in this trial","ALL","12 Years",{"count":58,"type":59},55,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients",[65],"Homozygous Familial Hypercholesterolemia","NOT_YET_RECRUITING","2025-08-14",{"date":69,"type":70},"2025-08-21","ACTUAL",{"date":72,"type":59},"2025-08",{"date":74,"type":59},"2027-12",{"name":5,"class":6},1]